Mr. Luc Gregoire reports

DEVONIAN NAMES KATHRYN J. GREGORY TO THE BOARD OF DIRECTORS AND GRANTS STOCK OPTIONS

Devonian Health Group Inc.'s board of directors has appointed pharmaceutical industry veteran Kathryn J. Gregory to the board, effective Feb. 28, 2024.

About Ms. Gregory

Ms. Gregory has over 25 years of executive leadership experience in start-up, mid-sized and large pharmaceutical and biotechnology companies. She has extensive experience in international business development, including corporate strategy, licensing, mergers and acquisitions, alliance management, and operational expertise in marketing, strategic sourcing and procurement. Ms. Gregory serves as head of business development at Rgenta Therapeutics Inc., a small-molecule ribonucleic acid modulation company, and concurrently as chief business officer of reVision Therapeutics Inc., a start-up ophthalmology company. Ms. Gregory currently serves as director of Carmell Corp., a bioaesthetics company focused on topical skin and hair care. Over her career, Ms. Gregory has led global business development functions for several pharmaceutical companies of all sizes. She received an MBA from Pepperdine University and a BA from the University of California, Berkeley.

"Ms. Gregory's deep knowledge and connections across the global pharmaceutical landscape will be critical in furthering Devonian's stated strategy to advance our clinical programs and plans for future commercialization and partnership," said Luc Gregoire, president and chief executive officer of the corporation.

"We are thrilled that someone of Kathryn's calibre is joining our board, bringing along her exceptional strategic and governance skills and experience. I look forward to working closely with her and drawing on her extensive biopharma experience," added David Baker, chairman of the corporation.

Grant of stock options

The board has approved the granting of 50,000 stock options to a director of the corporation, allowing the optionholder to acquire subordinate voting shares of the corporation at an exercise price of 21 cents for a period of 10 years in accordance with the terms and conditions of the stock option plan of the corporation. All the stock options granted the director of the corporation are vested immediately. The grant of the stock options is subject to the approval of the TSX Venture Exchange.

About Devonian Health Group Inc.

Devonian Health Group is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including, but not limited to, ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by the American Food and Drug Administration set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with its pharmaceutical offerings. Devonian Health Group was incorporated in 2015 and is headquartered in Quebec, Canada, where it owns a state-of-the-art extraction facility with full traceability from the seed to the pill. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the Exchange and on the OTCQB exchange.

We seek Safe Harbor.